# EDGAR Filing Document

**Accession Number:** 0001827855
**File Stem:** 0001683168-26-001056
**Filing Date:** 2026-2
**Character Count:** 50296
**Document Hash:** b26a7f7fc0d5618031728027a0e713d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-001056.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001683168-26-001056

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 44

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medicale Corp.
- **CENTRAL INDEX KEY:** 0001827855
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 981556944
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-250025
- **FILM NUMBER:** 26636598

**BUSINESS ADDRESS:**
- **STREET 1:** 9314 FOREST HILL BLVD
- **STREET 2:** #929
- **CITY:** WELLINGTON
- **STATE:** FL
- **ZIP:** 33411
- **BUSINESS PHONE:** 407-245-7339

**MAIL ADDRESS:**
- **STREET 1:** 9314 FOREST HILL BLVD
- **STREET 2:** #929
- **CITY:** WELLINGTON
- **STATE:** FL
- **ZIP:** 33411

?xml version='1.0' encoding='ASCII'? Medicale Corp. 10-Q

[**Table of Contents**](#q1_001)

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark One)

**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the quarterly period ended: **<u>December 31, 2025</u>**

or

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from **________________** to **________________**

Commission File Number: **<u>333-250025</u>**

---

| |
|:---|
| **Medicale Corp.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Nevada** | **98-1556944** |
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) |

---

**<u>9314 Forest Hill Blvd #929 Wellington, FL 33411</u>**

(Address of principal executive offices)

**<u>(407)245-7339</u>**

(Registrant's telephone number, including area code)

__________________________________________________________________

Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act: **<u>None</u>**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Name of each exchange**<br> **on which registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒&nbsp;&nbsp;&nbsp;&nbsp; No ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large, accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ☐ YES ☐ NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

5,920,000 common shares issued and outstanding as of February 17, 2026.

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page No.** |
| [PART I - FINANCIAL INFORMATION](#q1_002) | [PART I - FINANCIAL INFORMATION](#q1_002) |  |
| Item 1. | [Unaudited Condensed Financial Statements](#q1_003) | 4 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#q1_004) | 13 |
| Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#q1_005) | 16 |
| Item 4. | [Controls and Procedures](#q1_006) | 16 |
| [PART II - OTHER INFORMATION](#q1_007) | [PART II - OTHER INFORMATION](#q1_007) |  |
| Item 1. | [Legal Proceedings](#q1_008) | 18 |
| Item 1A. | [Risk Factors](#q1_009) | 18 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#q1_010) | 18 |
| Item 3. | [Defaults Upon Senior Securities](#q1_011) | 18 |
| Item 4. | [Mine Safety Disclosures](#q1_012) | 18 |
| Item 5. | [Other Information](#q1_013) | 18 |
| Item 6. | [Exhibits](#q1_014) | 18 |
| [SIGNATURES](#q1_015) | [SIGNATURES](#q1_015) | 19 |

---

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such forward-looking statements include, among others, those statements including the words "believes", "anticipates", "expects", "intends", "estimates", "plans" and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include changes in local, regional, national, or global political, economic, business, competitive, market (supply and demand) and regulatory conditions.

A description of these and other risks and uncertainties that could affect our business appears in the section captioned "Risk Factors" in our Annual Report on Form 10-K which we filed with the Securities and Exchange Commission ("SEC") on August 19, 2024 (the "Form 10-K"). The risks and uncertainties described under "Risk Factors" are not exhaustive.

Given these uncertainties, readers of this Quarterly Report on Form 10-Q ("Quarterly Report") are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

**PART I – FINANCIAL INFORMATION**

**ITEM 1. UNAUDITED CONDENSED FINANCIAL STATEMENTS**

**MEDICALE CORP.**

**CONDENSED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2025** | **September 30,**<br>**2025** |
|  | **(Unaudited)** | **(Audited)** |
| **ASSETS** |  |  |
| Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $– | $– |
| Total Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;**Total Assets** | $**–** | $**–** |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $7048 | $10644 |
| &nbsp;&nbsp;&nbsp;Accrued interest payable | 13154 | 11008 |
| &nbsp;&nbsp;&nbsp;Current liabilities from discontinued operations | 12000 | 12000 |
| Total Current Liabilities | 32202 | 33652 |
| &nbsp;&nbsp;&nbsp;Non-current convertible note payable | 113174 | 106434 |
| Total Long-term Liabilities | 113174 | 106434 |
| &nbsp;&nbsp;&nbsp;**Total Liabilities** | 145376 | 140086 |
| **STOCKHOLDERS' DEFICIT** |  |  |
| Common Stock: $0.0001 par value, 75,000,000 shares authorized, 5,920,000 shares issued and outstanding | 592 | 592 |
| Additional paid-in capital | 76320 | 76320 |
| Accumulated deficit | (222288) | (216998) |
| **Total Stockholders' Deficit** | (145376) | (140086) |
| &nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT** | $**–** | $**–** |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

**MEDICALE CORP.**

**CONDENSED STATEMENTS OF OPERATIONS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **December 31,**<br>**2025** | **December 31,**<br>**2024** |
| **Operating Expenses** |  |  |
| General and administration | $3144 | $14995 |
| &nbsp;&nbsp;&nbsp;Total operating expenses | 3144 | 14995 |
| **Net loss from operations** | (3144) | (14995) |
| **Other expense** |  |  |
| Interest expense | (2146) | (1685) |
| &nbsp;&nbsp;&nbsp;Total other expense | (2146) | (1685) |
| **Net loss before taxes** | (5290) | (16680) |
| Provision for income taxes | – | – |
| **Net loss** | $**(5290)** | $**(16680)** |
| **Net Loss Per Common Share – Basic and Diluted** | $(0.00) | $(0.00) |
| **Weighted Average Common Shares Outstanding** | 5920000 | 5920000 |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

**MEDICALE CORP.**

**CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**For the Three Months Ended December 31, 2025 and 2024**

**(Unaudited)**

**Three Months Ended December 31, 2025**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common stock** | **Common stock** | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance, September 30, 2025** | 5920000 | $592 | $76320 | $(216998) | $(140086) |
| Net loss | – | – | – | (5290) | (5290) |
| **Balance, December 31, 2025** | 5920000 | $592 | $76320 | $(222288) | $(145376) |

---

**Three Months Ended December 31, 2024**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common stock** | **Common stock** | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance, September 31, 2024** | 5920000 | $592 | $76320 | $(175845) | $(98933) |
| Net loss | – | – | – | (16680) | (16680) |
| **Balance, December 31, 2024** | 5920000 | $592 | $76320 | $(192525) | $(115613) |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

**MEDICALE CORP.**

**CONDENSED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **December 31,**<br>**2025** | **December 31,**<br>**2024** |
| **Cash Flows from Operating Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(5290) | $(16680) |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | (3596) | 4995 |
| &nbsp;&nbsp;&nbsp;Accrued interest payable | 2146 | 1685 |
| Net Cash Used in Operating Activities | (6740) | (10000) |
| **Cash Flows from Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of convertible notes | 6740 | 10000 |
| Net Cash Provided by Financing Activities | 6740 | 10000 |
| Net Change in Cash and Cash Equivalents |  |  |
| Cash and Cash Equivalents, beginning of period | – | 159 |
| Cash and Cash Equivalents, end of period | $– | $159 |
| Supplemental Disclosure Information: |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $– | $– |
| &nbsp;&nbsp;&nbsp;Cash paid for taxes | $– | $– |

---

See accompanying notes, which are an integral part of these unaudited condensed financial statements.

**MEDICALE CORP.**

**NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS**

**FOR THE THREE MONTHS ENDED DECEMBER 31, 2025**

 ****

**Note 1 – ORGANIZATION AND NATURE OF BUSINESS**

MEDICALE CORP ("the Company,", "we," "us" or "our") was incorporated in the State of Nevada on August 17, 2020. We plan to offer consulting services and distribution of the dietary supplements. A dietary supplement is a manufactured product intended to supplement the diet when taken by mouth as a pill, capsule, tablet, or liquid. A supplement can provide nutrients either extracted from food sources or synthetic, individually or in combination, in order to increase the quantity of their consumption.

On December 28, 2022, the previous majority shareholder of Medicale Corp. (the "Company") Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the "Shares") to Magenta Acres, Inc.

As a result of the acquisition of the Shares, Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company.

On December 28, 2022, the previous sole officer and director of the Company, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

As of the date of this report, the Company had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company's public reporting.

Our principal place of business is located 9314 Forest Hill Blvd #929 Wellington, FL 33411 which is provided to us on a rent free basis by our sole officer and director. Our telephone number is (407) 245-7339.

**Note 2 – GOING CONCERN**

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $222,288 and a working capital deficit of $32,202 as of December 31, 2025. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company's ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

**Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of presentation***

 ****

The accompanying unaudited condensed financial statements have been prepared in accordance with US GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended December 31, 2025 are not necessarily indicative of the results that may be expected for the year ending September 30, 2026. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for fiscal year 2024 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2025 included in the Company's [Form 10-K](https://www.sec.gov/Archives/edgar/data/1827855/000168316826000203/medicale_i10k-093025.htm) as filed with the Securities and Exchange Commission on January 12, 2026.

***Use of Estimates***

 ****

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

***Cash equivalents***

 ****

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. During the year ended September 30, 2024, the bank account, which was registered under the former Director of the Company, was written off upon the change of director as the Company was not able to recover the fund and bad debt expense of $159 was incurred in the Statements of Operations. As of December 31, 2025 and September 30, 2025, the Company had cash of $0.

***Fair Value of Financial Instruments***

 ****

FASB ASC Topic 820, "Fair Value Measurement," defines fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to recurring and nonrecurring fair value measurements of financial and non-financial assets and liabilities. The Company determines the fair values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure fair value.

The three levels are defined as follows:

---

| | |
|:---|:---|
| Level 1: | defined as observable inputs such as quoted prices in active markets; |
| Level 2: | defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and |
| Level 3: | defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. |

---

Due to its short-term nature, the carrying value of cash, accounts payable and accrued liabilities approximated fair value at December 31, 2025.

***Basic Income (Loss) Per Share***

 ****

The Company computes income (loss) per share in accordance with FASB ASC 260 "Earnings per Share". Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For the three months ended December 31, 2025 and 2024, convertible notes were potentially dilutive instruments and were not included in the calculation of diluted loss per shares as their effect would be antidilutive.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Schedule of antidilutive shares** | | | | |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2025** | **2025** | **2024** | **2024** |
|  | **(Shares)** | **(Shares)** | **(Shares)** | **(Shares)** |
| Convertible notes payable |  | 5616502 |  | 5485910 |

---

 ****

 ****

 **

***Recent Accounting Pronouncements***

 **

We have evaluated all recently issued, but not yet effective, accounting pronouncements and do not believe that these accounting pronouncements will have any material impact on our financial statements or disclosures upon adoption.

***Recent Adopted Accounting Standards***

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting* (Topic 280). The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of ASU 2023-07 has not had a material effect on the Company's statements and disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures ("ASU 2023-09"), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The adoption of ASU 2023-09 has not had a material effect on the Company's statements and disclosures.

**Note 4– COMMON STOCK**

 ****

The Company has 75,000,000, $0.0001 par value shares of voting common stock authorized.

All shares of common stock have voting rights and are identical. All holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

As of December 31, 2025 and September 30, 2025, the Company had 5,920,000 shares issued and outstanding.

*Voting Common Stock*

All shares of common stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

*Non-voting Common Stock*

 

All of the other terms of the Non-Voting Common Stock shall be identical to the Voting Common Stock, except for the right of first refusal that attaches to the Non-Voting Common Stock, as explained in the Company's Bylaws.

**Note 5– CONVERTIBLE NOTE PAYABLE**

---

| | | |
|:---|:---|:---|
| Schedule of convertible notes payable | **December 31,** | **September 30,** |
|  | **2025** | **2025** |
| December 2023 | $48186 | $48186 |
| March 2024 | 10602 | 10602 |
| June 2024 | 9288 | 9288 |
| September 2024 | 15509 | 15509 |
| December 2024 | 10000 | 10000 |
| March 2025 | 4371 | 4371 |
| June 2025 | 2021 | 2021 |
| September 2025 | 6457 | 6457 |
| December 2025 | 6740 | – |
|  | $113174 | $106434 |

---

On December 31, 2023, the Company entered into a Convertible Note agreement with a third party at $48,186 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on December 31, 2029. The note can be converted to the Company's common stock at $0.01 per share. As of December 31, 2025, the accrued interest is $7,720.

On March 31, 2024, the Company entered into a Convertible Note agreement with a third party at $10,602 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company's common stock at $0.04 per share. As of December 31, 2025, the accrued interest is $1,487.

On June 30, 2024, the Company entered into a Convertible Note agreement with a third party at $9,288 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company's common stock at $0.04 per share. As of December 31, 2025, the accrued interest is $1,118.

On September 30, 2024, the Company entered into a Convertible Note agreement with a third party at $15,509 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company's common stock at $0.15 per share. As of December 31, 2025, the accrued interest is $1,553.

On December 31, 2024, the Company entered into a Convertible Note agreement with a third party at $10,000 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company's common stock at $0.15 per share. As of December 31, 2025, the accrued interest is $800.

On March 31, 2025, the Company entered into a Convertible Note agreement with a third party at $4,371 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2031. The note can be converted to the Company's common stock at $0.15 per share. As of December 31, 2025, the accrued interest is $263.

On June 30, 2025, the Company entered into a Convertible Note agreement with a third party at $2,021 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on June 30, 2031. The note can be converted to the Company's common stock at $0.15 per share. As of December 31, 2025, the accrued interest is $81.

On September 30, 2025, the Company entered into a Convertible Note agreement with a third party at $6,457 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on September 30, 2031. The note can be converted to the Company's common stock at $0.15 per share. As of December 31, 2025, the accrued interest is $130.

On December 31, 2025, the Company entered into a Convertible Note agreement with a third party at $6,740 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on December 31, 2031. The note can be converted to the Company's common stock at $0.15 per share. As of December 31, 2025, the accrued interest is $0.

During the three months ended December 31, 2025 and 2024, the Company incurred $2,146 and $1,685 of note interest expense. As of December 31, 2025 and September 30, 2025, accrued interest payable was $13,154 and $11,008, respectively.

**Note 6 – DISCONTINUED OPERATION**

Through September, 2023, the Company's primary business was the sale of various consumer products and accessories. As of January 1, 2023, the Company ceased operations. On January 9, 2023, a change in control completed as the Company's former majority shareholder sold his 3,200,000 shares to an investor group for the consideration of $418,000. After the change in control, the Company's operations are determined by the new investor group. As such, the Company accounted for all of its revenue (loss), liabilities and results of operations up to January 1, 2023 as discontinued operations.

The Company has reclassified its previously issued financial statements to segregate the discontinued operations as of the earliest period reported.

The following table presents information related to the liabilities that were classified as current liabilities from discontinued operations in our balance sheets:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2025** | **September 30,<br> 2025** |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $12000 | $12000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities from discontinued operations | $12000 | $12000 |

---

**Note 7– SEGMENT REPORTING**

Operating segments comprised of the components of an entity in which separate information is available for evaluation by the Company's chief operating decision maker, or group of decision makers, in determining how to allocate resources in evaluating performance. The Company's chief operating decision maker ("CODM") is its Chief Executive Officer.

Through December 31, 2025, the Company is still in development stage and has not commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company's public reporting.

**Note 8– SUBSEQUENT EVENTS**

In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to December 31, 2025 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

**Forward-Looking Statements**

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to "common shares" refer to the common shares in our capital stock.

As used in this quarterly report, the terms "we, "us," "our" and "our company" mean Medicale Corp., unless otherwise indicated.

**General Overview**

Medicale Corp ("we," "our" or the "Company") was incorporated in the State of Nevada on August 17, 2020. To date we have not generated revenue from our business operations. Furthermore, as we are still in the early stages of developing our business and expect to operate at a loss as we grow our business. There is little historical financial information about our Company upon which to base an evaluation of our performance or to make a decision regarding an investment in our shares. We cannot guarantee that we will be successful in our business operations or that we will achieve significant, if any, level of market acceptance for our proposed business operations and products. Our business could be subject to any or all of the problems, expenses, delays and risks inherent in the establishment of a new business enterprise, including limited capital resources, possible changes in consumer interest, possible cost overruns due to price and cost increases in services or products we require.

We have never been subject to any bankruptcy proceedings. The principal place of business is now located at 9314 Forest Hill Blvd #929, Wellington, FL 33411. Our telephone number is (407) 245-7339.

As of the date of this report, the Company had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company's public reporting.

**Results of Operations**

The following summary of our results of operations should be read in conjunction with our financial statements for the three months ended December 31, 2025 and 2024 which are included herein.

*Three months ended December 31, 2025 compared to three months ended December 31, 2024*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | | |
|  | **December 31,** | **December 31,** | | |
|  | **2025** | **2024** |<br>**Changes** |<br>**%** |
| Operating expenses | $3144 | $14995 | $(11851) | (79%) |
| Other expenses | 2146 | 1685 | 461 | 27% |
| Net Loss | $5290 | $16680 | $(11390) | (68%) |

---

Our net loss for the three months ended December 31, 2025 was $5,290 compared with net loss of $14,995 for the three months ended December 31, 2024 due to the decrease in audit fees.

**Liquidity and Capital**

**Working Capital**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As of**<br>**December 31,**<br>**2025** | **As of**<br>**September 30,**<br>**2025** |<br>**Changes** |<br>**%** |
| Current Assets | $– | $– | $– |  |
| Current Liabilities | 32202 | 33652 | (1450) | (4%) |
| Working Capital Deficiency | $(32202) | $(33652) | $(1450) | 4% |

---

As at December 31, 2025 and September 30, 2025, our Company had cash of $0.

As at December 31, 2025, our Company had current liabilities of $32,202 as compared to $33,652 as of September 30, 2025. The decrease in current liabilities was due to the decrease in accounts payable and accrued liabilities.

As at December 31, 2025, our Company had a working capital deficiency of $32,202 compared with a working capital deficit of $33,652 as at September 30, 2025. The increase in working capital deficit was primarily due to the increase in accrued interest payable.

**Cash Flows**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | | |
|  | **December 31,** | **December 31,** | | |
|  | **2025** | **2024** |<br>**Changes** |<br>**%** |
| Cash flows used in operating activities | $(6740) | $(10000) | $3260 | (33%) |
| Cash flows provided by financing activities | 6740 | 10000 | (3260) | (33%) |
| Net changes in cash | $– | $– | $– | – |

---

*Cash Flow from Operating Activities*

We have not generated positive cash flow from operating activities. During the three months ended December 31, 2025, net cash used in operating activities was $6,740 compared to $10,000 used during the three months ended December 31, 2024.

Cash flows used in operating activities during the three months ended December 31, 2025, comprised of a net loss of $5,290 increased by a net change in operating liabilities of $1,450.

Cash flows used in operating activities during the three months ended December 31, 2024, comprised of a net loss of $16,680, decreased by a net change in operating liabilities of $6,680.

*Cash Flow from Investing Activities*

During the three months ended December 31, 2025 and 2024, our Company did not have any investing activities.

*Cash Flow from Financing Activities*

During the three months ended December 31, 2025 and 2024, net cash provided by financing activities was $6,740 and $10,000 for proceed from the issuance of convertible notes to non-affiliates for paying operating expenses, respectively.

**Going Concern**

As of December 31, 2025, we had an accumulated deficit of $222,288. We believe that its existing capital resources may not be adequate to enable it to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. The accompanying condensed financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. If we fail to generate positive cash flow or obtain additional financing, when required, we may have to modify, delay, or abandon some or all of our future business plans.

**Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

**Critical Accounting Policies**

The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements' estimates or assumptions could have a material impact on our financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Our financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented.

**Recent Accounting Pronouncements**

Management has considered all recent accounting pronouncements issued. Our company's management believes that these recent pronouncements will not have a material effect on our financial statements.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

As a "smaller reporting company," we are not required to provide the information required by this Item.

**ITEM 4. CONTROLS AND PROCEDURES.**

*Evaluation of Disclosure Controls and Procedures*

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC's rules. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of December 31, 2025. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were not effective as of December 31, 2025.

Our disclosure controls and procedures are not effective for the following reasons:

We did not maintain effective controls to identify and maintain segregation of duties in identifying, authorizing, approving, accounting for, and disclosing significant estimates, related-party transactions, significant unusual transactions, and other non-routine events and transactions. Specifically, we only have one individual, our sole officer and director, who reviews, evaluates, approves, and records transactions and initiates journal entries, approves journal entries, and posts journal entries to the general ledger. There is no independent review of any financial duties performed by this individual.

C*hanges in Internal Control Over Financial Reporting*

During the period covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

*Limitations on the Effectiveness of Internal Controls*

Our management do not expect that our disclosure controls and procedures or our internal control over financial reporting are or will be capable of preventing or detecting all errors or all fraud. Any control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements, due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns may occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risk.

**PART II – OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS.**

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

**ITEM 1A. RISK FACTORS.**

As a "smaller reporting company," we are not required to provide the information required by this Item.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.**

None

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES.**

None

**ITEM 4. MINE SAFETY DISCLOSURES.**

Not applicable.

**ITEM 5. OTHER INFORMATION.**

(a) None.

(b) None.

(c) *Rule 10b5-1 Trading Plans.* During the three months ended June 30, 2025, no director or Section 16 officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 31.1 | [Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](medicale_ex3101.htm) |
| 32.1 | [Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](medicale_ex3201.htm) |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Schema Document |
| 101.CAL | XBRL Calculation Linkbase Document |
| 101.DEF | XBRL Definition Linkbase Document |
| 101.LAB | XBRL Label Linkbase Document |
| 101.PRE | XBRL Presentation Linkbase Document |

---

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Medicale Corp.** | **Medicale Corp.** |
| Date: February 17, 2026 | By: | /s/ Chen Zu De |
|  |  | Chen Zu De |
|  |  | Chief Executive Officer and |
|  |  | Chief Financial Officer |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION PURSUANT TO**

**18 USC, SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES OXLEY ACT OF 2002**

I, Chen Zu De, the Chief Executive Officer and Chief Financial Officer of Medicale Corp. (the "Company") certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Dated: February 17, 2026 | /s/Chen Zu De |
|  | Chen Zu De |
|  | President Chief Executive Officer |
|  | and Chief Financial Officer |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO**

**18 USC, SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of, I, Chen Zu De, the Chief Executive Officer and Chief Financial Officer of Medicale Corp. (the "Company"), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the quarter ended December 31, 2025 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2. The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Form 10-Q.

---

| | |
|:---|:---|
| Dated: February 17, 2026 | /s/ Chen Zu De |
|  | Chen Zu De |
|  | Chief Executive Officer |
|  | and Chief Financial Officer |

---

The foregoing certification is being furnished as an exhibit to the Form 10-Q pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-Q for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.